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Background. The aim of this study was to determine which anticoagulant is superior for secondary prevention of cancer-
associated stroke, using changes in D-dimer levels as a biomarker for recurrent thromboembolic events. Methods. We conducted
a retrospective, single center observational study including patients with cancer-associated stroke who were treated with either
enoxaparin or warfarin. Blood samples for measuring the initial and follow-up D-dimer levels were collected at admission and
a median of 8 days after admission, respectively. Multiple logistic regression analysis was conducted to evaluate the factors that
influenced D-dimer levels after treatment. Results. Although the initial D-dimer levels did not differ between the two groups, the
follow-up levels were dramatically decreased in patients treated with enoxaparin, while they did not change with use of warfarin
(3.88 𝜇g/mL versus 17.42 𝜇g/mL, 𝑝 = 0.026). On multiple logistic regression analysis, use of warfarin (OR 12.95; 𝑝 = 0.001) and the
presence of systemic metastasis (OR 18.73; 𝑝 = 0.017) were independently associated with elevated D-dimer levels (≥10𝜇g/mL)
after treatment. Conclusion. In cancer-associated stroke patients, treatment with enoxaparin may be more effective than treatment
with warfarin for lowering the D-dimer levels. Future prospective studies are warranted to show that enoxaparin is better than
warfarin for secondary prevention in cancer-associated stroke.
1. Introduction
In recent years, there has been increasing interest in the
association between cancer and cerebrovascular disease.
However, the underlying pathophysiology of stroke in cancer
patients is still not fully understood [1–3]. Recently, cancer-
associated hypercoagulation has been proposed as the pri-
mary mechanism of stroke in these patients, particularly in
those without vascular risk factors or conventional stroke
etiologies [4–8]. Cancer-associated stroke has distinct char-
acteristics including infarction ofmultiple vascular territories
and markedly elevated D-dimer levels [7–13].
Keeping in mind the role of paraneoplastic hypercoag-
ulability in the development of thrombosis in the setting
of malignancy [1], strategies for prevention of recurrent
embolism in patients with cancer-associated stroke should
theoretically focus on correction of the coagulopathy using
anticoagulants. Based on the findings of large clinical trials,
low-molecular-weight heparin is the preferred agent for treat-
ment of venous thromboembolism in patients with cancer
[14, 15]. However, there is not much data regarding optimal
medications for secondary prevention of cancer-associated
stroke.
In this study, we aimed to determine whether enoxa-
parin is superior to warfarin for prevention of recurrent
stroke using changes in the D-dimer level, which is a
known biomarker for predicting cancer-associated throm-
botic events [12, 16, 17].
2. Materials and Methods
2.1. Patient Selection and Initial Workup. We analyzed data
from consecutive patients with cancer-associated stroke who
presented within 7 days of symptom onset between July 2006
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and December 2012. Cancer-associated stroke was identified
when the patient had (1) active cancer (diagnosis of cancer
within 6 months of stroke onset, any treatment for cancer
within the previous 6 months, or recurrent or metastatic
cancer) [18] and (2) ischemic stroke which could not be
explained by conventional strokemechanisms including large
artery atherosclerosis, cardioembolism, lacunar infarction, or
other etiologies (e.g., dissection) [19]. Among the patients
that met these criteria, we included subjects who were
treated with either enoxaparin or warfarin for prevention
of recurrent stroke. Patients who had primary intracranial
malignancy, an incomplete workup for stroke etiology (either
vascular or cardiologic studies), or a history of recent
surgery, myocardial infarction, or any signs of infectious
or immunological diseases which may influence plasma D-
dimer levels were excluded. Patients with stroke suspected
to be caused by the tumor itself (i.e., tumor emboli) or
cancer treatment (i.e., chemotherapy-induced stroke) were
also excluded. The Institutional Review Board in Samsung
Medical Center waived the need for written consent from the
patients and approved this study. The records of the patients
were anonymized prior to analysis.
Demographic and clinical data including age, sex, pre-
stroke medications, and vascular risk factors were collected
at the time of admission. The type of primary cancer,
histopathologic findings, and presence/absence of systemic
metastasis were also recorded. Blood samples were drawn
at the time of admission and were analyzed with a stan-
dard battery of biochemical and hematological tests. All
patients underwent brain MRI, vascular studies, 12-lead
electrocardiography, Holter and/or telemetry monitoring,
and noninvasive transthoracic echocardiography, which was
preferable in these critically ill patients with advanced cancer.
The patterns of acute stroke on diffusion-weighted imaging
(DWI) were reviewed and classified as single/multiple lesions
involving one vascular territory or multiple lesions involving
multiple vascular territories by two independent readers (K.
S. J. and J. H. M.). Both readers were blinded to the treatment
groups and D-dimer levels, and discordance in classification
was resolved by consensus.
2.2. Treatment and Outcomes. All subjects received either
twice-daily subcutaneous injections of enoxaparin (1.0mg/
kg) or oral warfarin with a target international normalized
ratio (INR) between 2.0 and 3.0. The warfarin group was
initially treated with heparin (intravenous unfractionated
heparin or enoxaparin) until reaching target levels of INR.We
reviewedmedical records to identifymajor bleeding events or
recurrent strokes during the course of treatment. A bleeding
event was considered major if it caused a fall in hemoglobin
of 2 g/dL or more, transfusion of at least 2 units of packed red
blood cells, or intracranial hemorrhage.
At the start of the study period,most patients were treated
with warfarin without measuring the D-dimer level after
initiating anticoagulation, since the role of monitoring D-
dimer levels for therapeutic effects had not yet been estab-
lished. However, after one patient with recurrent stroke was
found to have increasing D-dimer levels after switching from
enoxaparin to warfarin, patients were subsequently given
either enoxaparin or warfarin depending on the preference
of the individual physician with follow-up measurements of
D-dimer levels as a surrogate biomarker of recurrent stroke
[5, 11, 12]. The attending stroke physicians were sequentially
determined depending on the date of admission. Blood sam-
ples for follow-up D-dimer levels were collected at a median
of 8 days (interquartile range 6–11 days) after admission. The
D-dimer was measured by immunoturbidimetry on a STA-
R automated analyzer (Diagnostica Stago, Asnieres, France)
(reference values in our laboratory ≤0.5mg/mL).
2.3. Statistical Analyses. Statistical analyses were performed
using a commercially available software package (PASW
version 18.0; SPSS Inc., Chicago, IL, USA). All data are
presented as medians (25th–75th percentile) or numbers
(percentages). The Shapiro-Wilk test was used to confirm a
normal distribution. Since the distributions of all variables
were not normal (𝑝 < 0.05), Mann-Whitney 𝑈 tests were
conducted to compare continuous variables between groups.
Pearson’s chi-square or Fisher’s exact tests were used to com-
pare categorical variables. We used the Bonferroni correction
to account for multiple comparisons. Rates of recurrent
stroke and major bleeding events were computed by the
Kaplan-Meier method and compared using a two-sided log-
rank test. In addition,multiple logistic regression analysis was
conducted to evaluate the independent contribution of fac-
tors that influenced D-dimer levels after treatment. Variables
that were significant at 𝑝 < 0.2 on univariable analyses were
considered explanatory variables and were entered together
into a multivariable model. Results are reported as odds
ratios (OR) with 95% confidence intervals (CI). Moreover,
a multiple linear regression model was also performed to
identify factors associated with the change in D-dimer levels
between baseline and follow-up measurements. A 𝑝 value of
<0.05 was considered to be statistically significant.
3. Results
3.1. Patient Characteristics. Of the 104 patients with cancer-
associated stroke whowere admitted during the study period,
79 patients treated with either enoxaparin or warfarin were
included. Baseline characteristics of the patients are pre-
sented in Table 1. Age, sex, and the presence of vascular risk
factors did not differ significantly between the two groups.
Initial laboratory findings before treatment including D-
dimer levels were also comparable between groups. Multiple
lesions involving multiple vascular territories on DWI were
most frequently encountered in both groups.
In terms of cancer profiles, both groups had similar
characteristics including location of the primary cancer and
type of histopathology. However, the presence of systemic
metastasis at the time of strokewasmore prevalent in patients
treated with enoxaparin than warfarin (93.1% versus 62.0%;
𝑝 = 0.003).
3.2. Recurrent Stroke and Major Bleeding Events. During the
mean follow-up period of 4.9 months, recurrent strokes
were noted in only 1 (3.4%) patient treated with enoxaparin
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Table 1: Baseline characteristics.
Enoxaparin Warfarin
𝑝
(𝑁 = 29) (𝑁 = 50)
Male sex 18 (62.1%) 24 (48.0%) 0.227
Age, years 64 (53–67) 66 (60–72) 0.099
Vascular risk factors
Hypertension 6 (20.7%) 21 (42.0%) 0.054
Diabetes 7 (24.1%) 10 (20.0%) 0.666
Hyperlipidemia 1 (3.4%) 6 (12.0%) 0.252
Current smoker 7 (24.1%) 10 (20.0%) 0.666
Coronary artery disease 1 (3.4%) 1 (2.0%) >0.999
Laboratory findings on admission
Platelet, ×103/𝜇L 149 (89–249) 151 (108–229) 0.955
D-dimer, 𝜇g/mL 15.08 (4.34–37.32) 11.35 (2.84–37.25) 0.413
Fibrinogen, mg/dL 377 (294–500) 275 (184–432) 0.062
DWI∗ patterns 0.612
Single vascular territory 5 (17.2%) 11 (22.0%)
Single lesion 2 4
Multiple lesions 3 7
Multiple vascular territories 24 (82.8%) 39 (78.0%)
Prestroke medication
Antiplatelet agents 1 (3.4%) 8 (16.0%) 0.143
Anticoagulants 2 (6.9%) 4 (8.0%) >0.999
Cancer profiles
Primary cancer type 0.229
Lung 11 (37.9%) 27 (54.0%)
Gastrointestinal 6 (20.7%) 6 (12.0%)
Hepatobiliary 5 (17.2%) 10 (20.0%)
Breast-gynecologic 5 (17.2%) 2 (4.0%)
Other 2 (6.9%) 5 (10.0%)
Systemic metastasis 27 (93.1%) 31 (62.0%) 0.003
Adenocarcinoma 19 (65.5%) 35 (71.4%) 0.585
∗DWI: diffusion-weighted imaging.
and in 8 (16.0%) patients treated with warfarin. However,
the difference in stroke recurrence between the two groups
did not reach statistical significance primarily due to small
sample size (𝑝 = 0.249 by the log-rank test). Detailed features
of patients with recurrent stroke are shown in Table 2. Time
to recurrence was usually within 2months of the initial event,
and most patients had D-dimer levels that were >10 𝜇g/mL
and an INR above the lower limit (2.0). The incidence of
major bleeding events was similar between the two groups
(6.9% for enoxaparin versus 10.0% for warfarin; 𝑝 = 0.960 by
log-rank test).
3.3. Changes in D-Dimer Levels after Anticoagulation.
Follow-up D-dimer levels were available for 52 of 79 patients
(26 in each group). The median time from baseline to
follow-up measurement was not significantly different
between groups (8 days (5–12 days) for enoxaparin versus 8
days (6–9 days) for warfarin; 𝑝 = 0.686). Figure 1 illustrates
the changes in D-dimer levels after treatment. The initial
concentrations were comparable for patients treated with
enoxaparin and warfarin (17.06𝜇g/mL (5.62–37.48 𝜇g/mL)
for enoxaparin versus 17.78𝜇g/mL (9.57–39.54𝜇g/mL) for
warfarin; 𝑝 > 0.999). However, the follow-up levels were
dramatically decreased in patients treated with enoxaparin,
while they did not change significantly in those treated
with warfarin (3.88 𝜇g/mL (3.01–8.12𝜇g/mL) for enoxaparin
versus 17.42 𝜇g/mL (3.34–34.38 𝜇g/mL) for warfarin;
𝑝 = 0.026).
Since 7 of 9 patients who had a recurrent stroke had
D-dimer levels of ≥10 𝜇g/mL at the time of recurrence,
we divided the 52 patients into two groups according to
a cutoff value of 10 𝜇g/mL after treatment. As shown in
Table 3, treatment with warfarin, systemic metastasis, and
adenocarcinomaweremore prevalent in patients with follow-
upD-dimer levels ≥10 𝜇g/mL. Onmultiple logistic regression
analysis, anticoagulation using warfarin (adjusted OR 12.95;
95% CI, 2.89–57.94; 𝑝 = 0.001) and the presence of systemic
metastasis (adjusted OR 18.73; 95% CI, 1.69–207.48; 𝑝 =
0.017) were independently associated with D-dimer levels of
≥10 𝜇g/mL (Table 4).
Sensitivity analysis was subsequently performed using
different cutoff values for D-dimer levels after anticoagu-
lation, since the designation of ≥10 𝜇g/mL was somewhat
arbitrary. Oral anticoagulation and metastasis were also
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Table 2: Summary of detailed characteristics of subjects with recurrent stroke.
Number Sex Age Treatment
D-dimer level
(𝜇g/mL) on
admission
D-dimer level
(𝜇g/mL) at the
time of recurrence
INR∗ at the
time of
recurrence
Time to
recurrence
(months)
Primary
cancer
type
Adenocarcinoma Systemicmetastasis
1 Female 55 Warfarin 19.54 47.80 3.04 1.13 Lung Yes Yes
2 Male 72 Warfarin 1.91 2.96 1.48 0.80 Lung Yes No
3 Female 59 Warfarin 72.40 47.20 2.60 0.83 CBD Yes Yes
4 Male 61 Warfarin 60.00 39.72 2.62 0.46 Colon Yes Yes
5 Female 60 Warfarin 18.36 10.30 1.39 8.30 Lung Yes Yes
6 Female 51 Warfarin 11.74 57.93 5.51 19.63 Lung Yes Yes
7 Female 48 Warfarin 4.83 0.34 3.26 1.90 Lung Yes Yes
8 Female 75 Warfarin 14.87 14.74 2.06 0.37 Pancreas Yes Yes
9 Male 67 Enoxaparin 60.00 60.00 N/A† 0.43 CBD‡ Yes Yes
∗INR, international normalized ratio; †N/A: not applicable; ‡CBD: common bile duct.
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Figure 1: Changes in D-dimer levels after treatment: (a) enoxaparin; (b) warfarin.
independently associated with follow-up D-dimer levels
of ≥5 and ≥15 𝜇g/mL. In addition, multiple linear regres-
sion analysis demonstrated that treatment with enoxa-
parin was the only factor that was independently associ-
ated with a decline in D-dimer levels during treatment
(𝑝 = 0.020).
4. Discussion
In patients with cancer, thromboembolic complications neg-
atively affect quality of life and increase the risk of death.
Our results demonstrate that the risk of recurrence among
patients with cancer-associated stroke may be lower with use
of enoxaparin rather than oral warfarin for anticoagulation
therapy. In addition, we did not find a significant difference in
the rates of major bleeding events between the groups, which
is in agreement with previous reports [18, 20]. Although it
is known that low-molecular-weight heparin is superior to
warfarin for secondary prophylaxis of venous thromboem-
bolism in patients with active cancer [18], there is a paucity
of data regarding the optimal medication in patients with
cancer-associated stroke. To the best of our knowledge, this is
the first study to compare the efficacy and safety of different
types of anticoagulants for preventing recurrent stroke in this
population.
On a biochemical level, tissue factor is an important
component that triggers thromboembolic events in cancer
patients [21]. Accordingly, inhibition of the extrinsic coag-
ulation pathway that is initiated by tissue factor should
be the primary target for management of cancer-associated
thromboembolism. Heparin (both unfractionated and low-
molecular-weight), but not warfarin, can release tissue factor
pathway inhibitor (TFPI) which binds to the complex of
tissue factor, factor VIIa, and factor X, ultimately blocking
the production of factor Xa [22]. This may explain the
superiority of heparin over warfarin in reducing recurrent
thromboembolic complications in patients with active cancer
and corroborate the results of our study [15, 18].
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Table 3: Factors associated with high D-dimer levels.
D-dimer ≥10𝜇g/mL after treatment
No Yes 𝑝∗
(𝑛 = 31) (𝑛 = 21)
Male sex 18 (58.1%) 10 (47.6%) 0.458
Age, years 63 (55–71) 63 (55–70) 0.970
DWI patterns 0.724
Single vascular territory 6 (19.4%) 3 (14.3%)
Single lesion 3 2
Multiple lesions 3 1
Multiple vascular territories 25 (80.6%) 18 (85.7%)
Treatment 0.002
Enoxaparin 21 (67.7%) 5 (23.8%)
Warfarin 10 (32.3%) 16 (72.6%)
Cancer profiles
Primary cancer type 0.586
Lung 15 (48.4%) 12 (57.1%)
Gastrointestinal 4 (12.9%) 3 (14.3%)
Hepatobiliary 5 (16.1%) 5 (23.8%)
Breast-gynecologic 4 (12.9%) 1 (4.8%)
Other 3 (9.7%) 0 (0%)
Systemic metastasis 23 (74.2%) 20 (95.2%) 0.067
Adenocarcinoma 19 (61.3%) 17 (85.0%) 0.070
∗Other factors including vascular risk factors, premedications, and laboratory findings (platelet and fibrinogen) did not differ between the two groups (𝑝 >
0.2).
Table 4: Multiple logistic regression analysis: independent predic-
tors of D-dimer levels ≥10𝜇g/mL.
Estimated OR∗
Univariable Multivariable 𝑝
(95% CI†) (95% CI)
Treatment
Enoxaparin Reference Reference
Warfarin 6.72 (1.92–23.58) 12.95 (2.89–57.94) 0.001
Systemic metastasis 6.96(0.80–60.53)
18.73
(1.69–207.48) 0.017
Adenocarcinoma 3.58 (0.86–14.87) 2.41 (0.43–13.44) 0.314
∗OR: odds ratio; †CI: confidence interval.
The D-dimer is a degradation product of cross-linked
fibrinwhich reflects activation of the coagulation system; thus
elevated D-dimer levels are suggestive of a hypercoagulable
state [23, 24]. In addition, D-dimer levels are useful for prog-
nostication as well as judging of the effect of anticoagulation
treatment in patients with deep vein thrombosis, pulmonary
embolism, and cancer-associated stroke [5, 25–27]. Since
the life expectancy of our study population is shorter than
average due to the presence of advanced cancer, it is difficult
to achieve adequate follow-up until having recurrent embolic
events. For this reason, we used the D-dimer level as a
biomarker for monitoring treatment efficacy and predicting
stroke recurrence.
There are several limitations to our study. First, because
of its nature as a nonrandomized retrospective study, mea-
surement of follow-up D-dimer levels was completed in
different portion of the patients in each group. In the
initial period of this study, D-dimer levels over treatment
were not checked routinely due to lack of knowledge about
their role as a biomarker. Because most physicians chose
warfarin as maintenance anticoagulation at that time, many
patients in warfarin group were excluded because of missed
data. Moreover, treatment choice was dependent on the
judgment of individual physicians. Also, patients were not
routinely screened for venous thromboembolism which is
an important cause of elevated D-dimer. Therefore, we are
planning to perform a prospective, randomized trial to con-
firm our observational study results. Second, our results are
promising, but they are restricted by small sample size. Thus,
additional study in a large number of patients with cancer-
associated stroke is required. Finally, we defined cancer-
associated stroke by excluding patients with conventional
stroke mechanisms. To resolve this issue, identification of a
biomarker specific to cancer-associated stroke and associated
with pathophysiology is needed.
In conclusion, enoxaparin may be more effective than
warfarin for lowering the D-dimer levels in patients with
cancer-associated stroke. Future prospective studies are war-
ranted to show that enoxaparin is better than warfarin for
secondary prevention in cancer-associated stroke itself.
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